JP4646491B2 - イソフラボンおよび多価不飽和脂肪酸の組合せを含む、骨粗鬆症を予防するための組成物 - Google Patents
イソフラボンおよび多価不飽和脂肪酸の組合せを含む、骨粗鬆症を予防するための組成物 Download PDFInfo
- Publication number
- JP4646491B2 JP4646491B2 JP2002573015A JP2002573015A JP4646491B2 JP 4646491 B2 JP4646491 B2 JP 4646491B2 JP 2002573015 A JP2002573015 A JP 2002573015A JP 2002573015 A JP2002573015 A JP 2002573015A JP 4646491 B2 JP4646491 B2 JP 4646491B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- composition
- composition according
- acid
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title claims abstract description 24
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 14
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 235000008696 isoflavones Nutrition 0.000 title claims abstract description 14
- 150000002515 isoflavone derivatives Chemical class 0.000 title description 10
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical class CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000011712 vitamin K Chemical class 0.000 claims abstract description 36
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 36
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 35
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 34
- 229930003448 Vitamin K Chemical class 0.000 claims abstract description 34
- 239000011710 vitamin D Substances 0.000 claims abstract description 34
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 34
- 229940046010 vitamin k Drugs 0.000 claims abstract description 34
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 33
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 32
- 229940046008 vitamin d Drugs 0.000 claims abstract description 32
- 238000009472 formulation Methods 0.000 claims abstract description 10
- 239000002671 adjuvant Substances 0.000 claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- ZWSNUPOSLDAWJS-QNDFHXLGSA-N 6,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one Chemical compound OC[C@H]1O[C@@H](Oc2ccc(cc2)-c2coc3cc(O)c(O)cc3c2=O)[C@H](O)[C@@H](O)[C@@H]1O ZWSNUPOSLDAWJS-QNDFHXLGSA-N 0.000 claims abstract description 3
- 229940088594 vitamin Drugs 0.000 claims abstract 4
- 229930003231 vitamin Natural products 0.000 claims abstract 4
- 235000013343 vitamin Nutrition 0.000 claims abstract 4
- 239000011782 vitamin Substances 0.000 claims abstract 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 27
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 24
- 235000006539 genistein Nutrition 0.000 claims description 22
- 229940045109 genistein Drugs 0.000 claims description 22
- 235000005911 diet Nutrition 0.000 claims description 17
- 230000037213 diet Effects 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 10
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 10
- 230000011164 ossification Effects 0.000 claims description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 8
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 235000014106 fortified food Nutrition 0.000 claims description 7
- 239000007903 gelatin capsule Substances 0.000 claims description 7
- 239000011772 phylloquinone Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 235000007882 dietary composition Nutrition 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000012674 herbal formulation Substances 0.000 claims description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims description 4
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims description 4
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims description 4
- 229930182470 glycoside Natural products 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 235000007240 daidzein Nutrition 0.000 claims description 3
- -1 daidzein glycoside Chemical class 0.000 claims description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 3
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims description 3
- 235000008466 glycitein Nutrition 0.000 claims description 3
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 claims description 2
- YZXBAPSDXZZRGB-CGRWFSSPSA-N arachidonic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCC(O)=O YZXBAPSDXZZRGB-CGRWFSSPSA-N 0.000 claims description 2
- MBMBGCFOFBJSGT-SFGLVEFQSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O MBMBGCFOFBJSGT-SFGLVEFQSA-N 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 238000009477 fluid bed granulation Methods 0.000 claims description 2
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 claims description 2
- 238000009478 high shear granulation Methods 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 claims description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims 2
- 235000019175 phylloquinone Nutrition 0.000 claims 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims 2
- 229960001898 phytomenadione Drugs 0.000 claims 2
- 235000005282 vitamin D3 Nutrition 0.000 claims 2
- 239000011647 vitamin D3 Substances 0.000 claims 2
- 229940021056 vitamin d3 Drugs 0.000 claims 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 10
- 102000004067 Osteocalcin Human genes 0.000 description 10
- 108090000573 Osteocalcin Proteins 0.000 description 10
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 206010030247 Oestrogen deficiency Diseases 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 206010065687 Bone loss Diseases 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000002338 glycosides Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229930012930 isoflavone derivative Natural products 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- DTIVBBCEMQZIEQ-UHFFFAOYSA-N octadeca-6,9,12-triene Chemical compound CCCCCC=CCC=CCC=CCCCCC DTIVBBCEMQZIEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000021139 traditional diet Nutrition 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
を含み、そのため、場合により、
をさらに含むことを特徴とする、組成物を意味する。
以下の実験セクションでは、二重エネルギーX線吸収測定法(DXA)を用いて、骨無機質密度を測定した。
群1の擬似手術された動物に比して、高または低ビタミンKおよびD食餌による群2または3の卵巣切除動物は、期待されたとおりのBMDの有意な減少を示した。高ビタミンKおよびDの飼料による群2は、低ビタミンKおよびD飼料による群3の動物より有意に良好にはBMDを保持しなかった。
エストロゲン欠乏は、より高レベルの血清オステオカルシンを生じる骨代謝回転の増大を招く。対照群に比して、群2および3は、有意に上昇したオステオカルシンレベルを示したが、低ビタミンKおよびD飼料によった群3の血清オステオカルシンレベルも、やはり、高ビタミンKおよびDレベルによる群2の血清オステオカルシンレベルより有意に高かった。低ビタミンKおよびDレベルにn−3PUFAまたはゲニステインを補充したところ、すなわち群4および5では、対照値までオステオカルシンレベルが低下した。n−3PUFAとゲニステインとの間には、効果における有意差は皆無であった。n−3PUFAおよびゲニステインを含有する高ビタミンKおよびD飼料による群6は、最も優れた結果、すなわちオステオカルシンレベルに対する最も優れた効果を示し、群4より有意に良好であった。結果を表3に示す。
エストロゲン欠乏は、デオキシピリジノリン(DPD)排出の有意な増大を生じて、それは、低ビタミンKおよびD飼料による群では、高ビタミンKおよびD含量の飼料によるそれに比して有意に高かった。n−3PUFA補充の効果は、高ビタミンKおよびD飼料のそれに匹敵した。低ビタミンKおよびDレベルのゲニステイン含有飼料(群5)は、DPD排出を対照群の値まで回復した。群6は、群5に比して、有意なそれ以上の向上を示さなかった。結果を表4に示すが、これは、試験された化合物のうちでは、ゲニステインが対照DPD排出値を回復するのに最も効果的な化合物であり(群5)、一方、飼料へのn−3PUFAの添加(群4)は、高ビタミンKおよびD食餌によって得られた効果(群2)を超えなかった。
Claims (25)
- 下記の成分:
(a)少なくとも一種類のイソフラボン、一種類のイソフラボングリコシド、またはそれらの混合物;
(b)少なくとも一種類の多価不飽和脂肪酸;ならびに
(c)場合により、ビタミンD、ビタミンD誘導体、ビタミンK、ビタミンK誘導体、およびそれらの混合物からなる群より選択されるビタミン;
からなる骨粗鬆症の予防に有用な組成物。 - 成分(a)が、ダイゼイン、ダイゼイングリコシド、グリシテイン、グリシテイングリコシド、ゲニステインおよびゲニステイングリコシドからなる群より選択される、請求項1記載の組成物。
- 成分(a)がゲニステイン、ゲニスチンまたはそれらの混合物である、請求項1または2記載の組成物。
- 成分(b)が、16〜24個の炭素原子を有し、複数の不飽和炭素−炭素二重結合を含む、多価不飽和脂肪酸である、請求項1〜3のいずれか一項記載の組成物。
- 18〜22個の炭素原子を有する多価不飽和脂肪酸による、請求項4記載の組成物。
- 18、20または22個の炭素原子を有する多価不飽和脂肪酸による、請求項4記載の組成物。
- 多価不飽和脂肪酸がn−3多価不飽和脂肪酸である、請求項4記載の組成物。
- 成分(b)が、リノール酸、リノレン酸、エイコサテトラエン酸、エイコサペンタエン酸およびドコサヘキサエン酸からなる群より選択される、請求項1〜6のいずれか一項記載の組成物。
- 成分(b)が、(cis, cis, cis-)9,12,15−オクタデカトリエン酸、(cis, cis, cis-)6,9,12−オクタデカトリエン酸、(cis-)5,8,11,14−エイコサテトラエン酸、(cis-)5,8,11,14,17−エイコサペンタエン酸および(cis-)4,7,10,13,16,19−ドコサヘキサエン酸からなる群より選択される、請求項1〜8のいずれか一項記載の組成物。
- 成分(a)1mgあたり5〜200mgの成分(b)を含む、請求項1〜9のいずれか一項記載の組成物。
- 成分(a)1mgあたり20〜50mgの成分(b)を含む、請求項1〜9のいずれか一項記載の組成物。
- 成分(c)が、ビタミンD3、ビタミンK1およびそれらの混合物からなる群より選択される、請求項1〜11のいずれか一項記載の組成物。
- 該組成物の総重量を基準として0.1〜20重量%の範囲内の量の佐剤または賦形剤が添加された、請求項1〜12のいずれか一項記載の組成物。
- 成分(d)が、澱粉、澱粉誘導体、セルロース、セルロース誘導体、ポリオールおよびそれらの混合物からなる群より選択される、請求項13記載の組成物。
- セルロース誘導体がヒドロキシプロピルメチルセルロース(HPMC)、メチルセルロース(MC)またはそれらの混合物である、請求項14記載の組成物。
- 濃縮物、顆粒剤、錠剤、ハードまたはソフトゼラチンカプセルに充填されたペースト剤、および発泡処方物からなる群より選択される形態で与えられる、請求項1〜15のいずれか一項記載の組成物。
- 成分の単純な粉末混合物である濃縮物の形態である、請求項16記載の組成物。
- 流動層造粒、高剪断造粒、押出し、噴霧乾燥または湿式造粒によって得られ得る、請求項16または17記載の散剤もしくは顆粒剤の形態の組成物。
- 食餌組成物または生薬処方物を製造するための請求項1〜18のいずれか一項記載の組成物の使用。
- 強化食品、強化飼料、飲料、錠剤、顆粒剤、ハードまたはソフトゼラチンカプセルに充填されたペースト剤、および発泡処方物からなる群より選択される該組成物もしくは該処方物を製造するための請求項1〜18のいずれか一項記載の組成物の使用。
- 請求項1〜18のいずれか一項記載の組成物を含む食餌組成物。
- 強化食品、強化飼料または飲料の形態である、請求項21記載の食餌組成物。
- 錠剤、顆粒剤、ハードもしくはソフトゼラチンカプセルに充填されたペースト剤、または発泡処方物の形態の、請求項1〜18のいずれか一項記載の組成物を含有する生薬処方物。
- 哺乳動物における骨粗鬆症を予防し、骨形成を刺激するための予防用の、請求項1〜23のいずれか一項記載の組成物。
- 哺乳動物における骨粗鬆症の治療又は予防、および骨形成に用いるための組成物であって、下記の成分:
(a)1日あたり5〜100mgの範囲内にある消費を生じるような濃度であるゲニステイン;
(b)リノール酸、リノレン酸、エイコサテトラエン酸、エイコサペンタエン酸およびドコサヘキサエン酸からなる群より選択される多価不飽和脂肪酸;
(c)ビタミンD、ビタミンD3およびそれらの混合物からなる群より選択されるビタミンであって、1日あたり5〜50μgの範囲内にある消費を生じるような濃度であるビタミン;
(d)ビタミンK、ビタミンK1およびそれらの混合物からなる群より選択されるビタミンであって、1日あたり0.050〜10mgの範囲内にある消費を生じるような濃度であるビタミン;ならびに
(e)場合により、該組成物の総重量を基準として0.1〜20重量%の範囲内の量の佐剤または賦形剤
からなる組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01106520 | 2001-03-15 | ||
PCT/EP2002/002646 WO2002074308A1 (en) | 2001-03-15 | 2002-03-11 | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004532829A JP2004532829A (ja) | 2004-10-28 |
JP4646491B2 true JP4646491B2 (ja) | 2011-03-09 |
Family
ID=8176795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002573015A Expired - Fee Related JP4646491B2 (ja) | 2001-03-15 | 2002-03-11 | イソフラボンおよび多価不飽和脂肪酸の組合せを含む、骨粗鬆症を予防するための組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7635692B2 (ja) |
EP (3) | EP1370257B1 (ja) |
JP (1) | JP4646491B2 (ja) |
KR (1) | KR100875800B1 (ja) |
CN (1) | CN100389765C (ja) |
AT (1) | ATE367810T1 (ja) |
BR (1) | BRPI0208103B8 (ja) |
CA (1) | CA2440261C (ja) |
DE (1) | DE60221367T2 (ja) |
ES (1) | ES2289097T3 (ja) |
MX (1) | MXPA03008137A (ja) |
WO (1) | WO2002074308A1 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050090457A1 (en) * | 2002-02-15 | 2005-04-28 | N.V. Nutricia | Method of treating mammals with genistein and/or genistein analogues |
ITMI20022723A1 (it) * | 2002-12-20 | 2004-06-21 | Marfarma S R L Ora Marfarma Holding Spa | Composizioni per il trattamento della sindrome post-menopausa. |
KR101573316B1 (ko) * | 2004-03-29 | 2015-12-01 | 와이어쓰 엘엘씨 | 종합비타민 및 무기물 영양 보충제 |
CN100351248C (zh) * | 2004-07-05 | 2007-11-28 | 南京大学 | 染料木素衍生物及其制法和用途 |
US7601370B2 (en) | 2004-07-28 | 2009-10-13 | Abbott Laboratories | Method for controlling body weight in estrogen-insufficient women |
WO2006087164A1 (en) | 2005-02-15 | 2006-08-24 | Dsm Ip Assets B.V. | Compositions containing polysaccharides |
WO2006088418A1 (en) * | 2005-02-18 | 2006-08-24 | Core Competence Sweden Ab | A composition comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids distributed in an effervescent base |
US8242100B2 (en) * | 2006-02-28 | 2012-08-14 | Nestec Sa | Compositions and methods for inducing bone growth and inhibiting bone loss |
CA2643973A1 (en) * | 2006-02-28 | 2007-09-07 | Council Of Scientific And Industrial Research | Pharmaceutical composition containing butea isoflavones for the prevention /treatment of bone disorders and a process for the preparation thereof |
EP2004169B1 (en) | 2006-04-12 | 2012-08-08 | Unilever PLC | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
ES2393212T3 (es) * | 2006-04-12 | 2012-12-19 | Unilever N.V. | Composición oral con un efecto antienvejecimiento sobre la piel |
EP2004161B8 (en) * | 2006-04-12 | 2013-04-17 | Unilever PLC | Oral composition comprising dha and genistein for enhancing skin properties |
WO2007128461A1 (en) * | 2006-05-10 | 2007-11-15 | Dsm Ip Assets B.V. | Animal food composition comprising genistein and polyunsaturated fatty acids |
US20070298079A1 (en) * | 2006-06-26 | 2007-12-27 | Tropicana Products, Inc. | Food fortified with omega-3 fatty acids |
PL2046312T3 (pl) * | 2006-07-14 | 2021-02-08 | Kaydence Pharma As | Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2 |
EP1897530A1 (en) * | 2006-09-08 | 2008-03-12 | DSMIP Assets B.V. | Skin care composition |
WO2008119544A1 (en) | 2007-04-02 | 2008-10-09 | Dsm Ip Assets B.V. | Novel use of genistein |
US8211947B2 (en) * | 2008-01-28 | 2012-07-03 | Guillermo Selman-Housein Sosa | Composition and method for treating and preventing musculoskeletal and connective tissue disorders |
CN101537170B (zh) * | 2008-03-17 | 2012-05-30 | 哈药集团制药六厂 | 一种预防骨质疏松和骨关节病的组合物 |
CN101574338B (zh) * | 2008-05-05 | 2012-01-11 | 上海医药工业研究院 | 一种抑制芳香化酶活性的药物组合物及其应用 |
DE202009018772U1 (de) * | 2008-06-03 | 2013-03-15 | John Ray Biffin | Zusammensetzung enthaltend Vitamin K und ihre Verwendung |
TR201004464A2 (tr) * | 2010-06-03 | 2012-11-21 | B�Lg�� Mahmut | Kemik erimesi için formülasyon. |
CN102356877A (zh) * | 2011-10-14 | 2012-02-22 | 李泼 | Cbp养钙冲剂 |
WO2013089654A1 (en) * | 2011-12-16 | 2013-06-20 | Mahmut Bilgic | Effervescent formulations comprising genistein |
FR3005419B1 (fr) | 2013-05-13 | 2015-09-04 | Agronomique Inst Nat Rech | Utilisation d'une association de deux composes pour le traitement et/ou la prevention de troubles osseux |
WO2016099495A1 (en) * | 2014-12-17 | 2016-06-23 | Hill's Pet Nutrition, Inc. | Method and composition for reducing hyperthyroidism |
CN109527538A (zh) * | 2018-11-07 | 2019-03-29 | 云南金霓尔生物科技有限公司 | 一种治疗骨质疏松促进吸收的营养剂及其制备方法 |
CN112401066B (zh) * | 2020-11-18 | 2022-10-28 | 乖宝宠物食品集团股份有限公司 | 一种利于维持骨骼健康的宠物食品 |
CN112790278B (zh) * | 2021-01-22 | 2022-10-28 | 乖宝宠物食品集团股份有限公司 | 一种维持骨骼健康的全价宠物罐头食品 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06157303A (ja) * | 1992-08-21 | 1994-06-03 | Scotia Holdings Plc | 脂肪酸治療 |
JPH10513162A (ja) * | 1995-02-01 | 1998-12-15 | オーソモル・ファーマツォイティッシェ・フェルトリープス・ゲー・エム・ベー・ハー | 骨形成の疾患に作用する剤 |
JPH119221A (ja) * | 1997-06-26 | 1999-01-19 | Honen Corp | 抗骨粗鬆症組成物 |
JP2000191526A (ja) * | 1998-12-25 | 2000-07-11 | Marumiya:Kk | 骨形成促進及び抗骨粗鬆症組成物 |
US6150399A (en) * | 1998-06-30 | 2000-11-21 | Abbott Laboratories | Soy-based nutritional products |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04253908A (ja) * | 1990-12-28 | 1992-09-09 | Nippon Oil & Fats Co Ltd | 骨粗鬆症治療薬 |
GB9112052D0 (en) * | 1991-06-05 | 1991-07-24 | Efamol Holdings | Fatty acid treatment |
IT1299191B1 (it) * | 1998-06-23 | 2000-02-29 | Sigma Tau Healthscience Spa | Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa |
WO2000069272A1 (en) * | 1999-05-18 | 2000-11-23 | Unilever N.V. | Fat containing products |
FR2817866B1 (fr) * | 2000-12-13 | 2005-01-07 | Theramex | Procede d'extraction de melanges flavoniques et utilisation des melanges ainsi obtenus en dermocosmetique, en alimentation et en pharmacie |
-
2002
- 2002-03-11 EP EP02726156A patent/EP1370257B1/en not_active Expired - Lifetime
- 2002-03-11 KR KR1020037012046A patent/KR100875800B1/ko active IP Right Grant
- 2002-03-11 AT AT02726156T patent/ATE367810T1/de not_active IP Right Cessation
- 2002-03-11 MX MXPA03008137A patent/MXPA03008137A/es active IP Right Grant
- 2002-03-11 WO PCT/EP2002/002646 patent/WO2002074308A1/en active IP Right Grant
- 2002-03-11 ES ES02726156T patent/ES2289097T3/es not_active Expired - Lifetime
- 2002-03-11 EP EP07014076A patent/EP1852115A1/en not_active Withdrawn
- 2002-03-11 CN CNB028066634A patent/CN100389765C/zh not_active Expired - Fee Related
- 2002-03-11 EP EP07014063A patent/EP1854462A1/en not_active Withdrawn
- 2002-03-11 CA CA2440261A patent/CA2440261C/en not_active Expired - Lifetime
- 2002-03-11 DE DE60221367T patent/DE60221367T2/de not_active Expired - Lifetime
- 2002-03-11 JP JP2002573015A patent/JP4646491B2/ja not_active Expired - Fee Related
- 2002-03-11 US US10/471,890 patent/US7635692B2/en not_active Expired - Fee Related
- 2002-03-11 BR BR0208103-2 patent/BRPI0208103B8/pt not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06157303A (ja) * | 1992-08-21 | 1994-06-03 | Scotia Holdings Plc | 脂肪酸治療 |
JPH10513162A (ja) * | 1995-02-01 | 1998-12-15 | オーソモル・ファーマツォイティッシェ・フェルトリープス・ゲー・エム・ベー・ハー | 骨形成の疾患に作用する剤 |
JPH119221A (ja) * | 1997-06-26 | 1999-01-19 | Honen Corp | 抗骨粗鬆症組成物 |
US6150399A (en) * | 1998-06-30 | 2000-11-21 | Abbott Laboratories | Soy-based nutritional products |
JP2000191526A (ja) * | 1998-12-25 | 2000-07-11 | Marumiya:Kk | 骨形成促進及び抗骨粗鬆症組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20040082523A1 (en) | 2004-04-29 |
CN100389765C (zh) | 2008-05-28 |
JP2004532829A (ja) | 2004-10-28 |
EP1370257A1 (en) | 2003-12-17 |
ATE367810T1 (de) | 2007-08-15 |
EP1370257B1 (en) | 2007-07-25 |
BRPI0208103B1 (pt) | 2018-02-14 |
EP1854462A1 (en) | 2007-11-14 |
MXPA03008137A (es) | 2003-12-12 |
WO2002074308A1 (en) | 2002-09-26 |
EP1852115A1 (en) | 2007-11-07 |
CA2440261C (en) | 2014-05-27 |
BRPI0208103B8 (pt) | 2021-05-25 |
KR20040025906A (ko) | 2004-03-26 |
DE60221367D1 (de) | 2007-09-06 |
US7635692B2 (en) | 2009-12-22 |
KR100875800B1 (ko) | 2008-12-24 |
CA2440261A1 (en) | 2002-09-26 |
ES2289097T3 (es) | 2008-02-01 |
DE60221367T2 (de) | 2008-04-03 |
BR0208103A (pt) | 2004-03-02 |
CN1501799A (zh) | 2004-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4646491B2 (ja) | イソフラボンおよび多価不飽和脂肪酸の組合せを含む、骨粗鬆症を予防するための組成物 | |
EP1294236B1 (en) | Animal food and method | |
EP1216024B1 (en) | Formulation for menopausal women | |
US6444242B1 (en) | Microencapsulated oil or fat product | |
JP4430233B2 (ja) | 骨粗鬆症の予防および/または治療のための、プロピオニルl−カルニチンおよびゲニステインを含む組成物 | |
AU2001265273A1 (en) | Animal food and method | |
EP1988891B1 (en) | Compositions and methods for inducing bone growth and inhibiting bone loss | |
MX2010008906A (es) | Uso combinado de 25-hidroxi-vitamina d3 y vitamina d3 para mejorar la densidad mineral osea y para tratar osteoporosis. | |
KR20160148028A (ko) | 지용성 비타민 제형 | |
JP2009537467A (ja) | 前立腺癌に対する新規活性物 | |
JP4714343B2 (ja) | 骨吸収増加治療用の植物抽出物 | |
JP3459932B2 (ja) | 抗骨粗鬆症組成物 | |
WO2002034073A2 (de) | Zusammensetzungen enthaltend flavonoide und phloridzin oder phloretin | |
DE602004001519T2 (de) | Zusammensetzungen aus naturprodukten und verwendung dafür | |
Darroch | Vitamin A in swine nutrition | |
JP2004357507A (ja) | ペット用サプリメント | |
NL9401958A (nl) | Met eierschalenmeel verrijkt melkprodukt. | |
Bertrandt et al. | Polyunsaturated fatty acid (PUFA) changes in serum and liver of undernourished rats given dietary vitamin B6 supplementation | |
JPH119221A (ja) | 抗骨粗鬆症組成物 | |
Okafor et al. | A Comparative Study of the Ameliorative Effects of Skimmed Milk and Tuna Fish in the Dietary Management of Dexamethasone Sodium Phosphate Induced Osteoporotic Female Wistar Rats | |
Blažek et al. | The Effect of α-Tocopherol Acetate on Plasma Esterified Cholesterol in Patients with Chronic Liver Disease/Einfluß des α-Tokopherolazetats auf Plasmacholesterolester bei Kranken mit chronischen Leberstörungen/L'action de l'acétate d'α-tocophérol sur la fraction estérifiée du cholésterol plasmatique chez les malades souffrant d'affections hépatiques chroniques | |
JP2003063970A (ja) | 抗骨粗鬆症組成物 | |
AU2005200907B2 (en) | Formulation for menopausal women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050310 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20061130 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20061207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081125 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090324 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090331 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090427 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090525 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090525 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100924 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101109 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101207 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131217 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4646491 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |